Caris Life Sciences director buys 31K shares
Caris Life Sciences director Jeff L. Vacirca purchased 31,050 shares of Common Stock in an open-market transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Caris Life Sciences director Jeff L. Vacirca purchased 31,050 shares of Common Stock in an open-market transaction. The weighted average purchase price was $16.149 per share, with individual trade prices ranging from $16.13 to $16.15. Following this purchase, he directly owns 49,671 shares.
Insider Trade Summary
Net Buyer: 31,050 shares
Net Buy
1 txn
Insider
Vacirca Jeff L
Role
Director
Bought
31,050 shs ($501K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 31,050 | $16.149 | $501K |
Holdings After Transaction:
Common Stock — 49,671 shares (Direct)
Footnotes (1)
- F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.13 to $16.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote
Key Figures
Shares purchased: 31,050 shares
Weighted average price: $16.149 per share
Price range: $16.13–$16.15 per share
+1 more
4 metrics
Shares purchased
31,050 shares
Open-market purchase of Common Stock on 2026-05-11
Weighted average price
$16.149 per share
Average price paid across multiple trades
Price range
$16.13–$16.15 per share
Range of execution prices for the purchase
Shares owned after transaction
49,671 shares
Director’s direct holdings following the purchase
Key Terms
open-market purchase, weighted average price, Common Stock, transaction code P
4 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
transaction code P regulatory
"transaction_code: P"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Caris Life Sciences (CAI) disclose?
Caris Life Sciences disclosed that director Jeff L. Vacirca bought 31,050 shares of Common Stock in an open-market transaction. This increased his direct ownership to 49,671 shares following the reported purchase.
Was the Caris Life Sciences (CAI) insider trade an open-market purchase?
Yes. The filing classifies the transaction as an open-market purchase of Common Stock. The Form 4 uses transaction code P, indicating a purchase in the open market or a private transaction at market-related prices.
What does the weighted average price mean in the CAI Form 4 filing?
The weighted average price of $16.149 reflects multiple trade executions between $16.13 and $16.15. The footnote notes that detailed trade-by-trade pricing information is available upon request from the company, its security holders, or the SEC staff.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates